Form 4: Celldex Therapeutics SVP Granted Significant Stock Options

Margo Heath-Chiozzi, SVP of Regulatory Affairs at Celldex Therapeutics, was granted 82,000 incentive stock options with an exercise price of $19.53, vesting over four years.

Summary

• Margo Heath-Chiozzi, SVP of Regulatory Affairs at Celldex Therapeutics, Inc. (CLDX), was granted 82,000 incentive stock options.
• The options have an exercise price of $19.53 per share.
• The grant date for these options was June 5, 2025.
• The options were granted under the company's 2021 Omnibus Equity Incentive Plan.
• Vesting schedule: 25% of the options will vest on June 5, 2026, with the remaining portion vesting quarterly in equal amounts over the subsequent 12 quarters (three years).
• The options have an expiration date of June 5, 2035.
• Following this transaction, Margo Heath-Chiozzi beneficially owns 82,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of a significant number of incentive stock options to a key executive is a positive development for the individual, providing a strong financial incentive. For the company, it represents a standard compensation practice aimed at retaining and motivating talent, aligning executive interests with long-term shareholder value.

Positives

• The grant of 82,000 incentive stock options serves as a significant incentive for Margo Heath-Chiozzi, aligning her interests with shareholder value creation.
• The options were granted under the company's established 2021 Omnibus Equity Incentive Plan, indicating a structured approach to executive compensation.

Future Outlook

The vesting schedule indicates a future commitment and incentive structure for the SVP of Regulatory Affairs, aligning her long-term interests with the company's performance through June 2029.

Industry Context

This Form 4 filing reports a routine executive compensation event (stock option grant) within the biotechnology or pharmaceutical industry, where equity incentives are a common practice to attract, retain, and motivate key personnel, especially in roles critical for regulatory approvals and product development like Regulatory Affairs.

Corporate Governance

Related Party Transactions

• The transaction involves an incentive stock option grant from Celldex Therapeutics, Inc. to Margo Heath-Chiozzi, an SVP of Regulatory Affairs, which is a related party transaction as it is between the company and one of its officers. This is a standard compensation arrangement.

Stakeholder Impact

• Shareholders: The grant of options dilutes existing shareholder equity over time as options are exercised, but it also aims to incentivize management to increase shareholder value.
• Employees: This specific filing relates to a senior executive's compensation and does not directly impact other employees, though it reflects the company's overall compensation philosophy.

Next Steps

• The vesting of 25% of the options on June 5, 2026.
• Subsequent quarterly vesting of the remaining options over the following 12 quarters.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Stock Options, Incentive Stock Option, Form 4, SEC Filing, Insider Transaction, Executive Compensation, Equity Incentive Plan, Margo Heath-Chiozzi, Regulatory Affairs